CNSY NASDAQ
Cerenome, Inc.
1W: -19.6%
1M: -45.6%
YTD: -59.2%
$1.60
-0.18 (-10.11%)
Weekly Expected Move ±10.1%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$11.0M
52W Range1.54-23.5
Volume226,354
Avg Volume116,187
Beta1.39
Dividend—
Analyst Ratings
Company Info
CEOMarc H. Hedrick
Employees28
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-08-03
Websiteplustherapeutics.com
6420 Levit Green Blvd
Houston, TX 77021
US
Houston, TX 77021
US
About Cerenome, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Latest News
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| van Es-Johansson An | M-Exempt | 921 | — | 2026-10-01 |
| van Es-Johansson An | M-Exempt | 921 | — | 2026-10-01 |
| Hawkins Richard J | M-Exempt | 921 | — | 2026-10-01 |
| Hawkins Richard J | M-Exempt | 921 | — | 2026-10-01 |
| Sims Andrew John Hug | M-Exempt | 1,533 | — | 2026-10-01 |